Clinical trial · Interventional
Weekly Cisplatin or Nedaplatin Concurrent With Intensity-modulated Radiation Therapy in Nasopharyngeal Carcinoma
A Randomized Phase III Study of Concurrent Weekly Nedaplatin or Cisplatin With IMRT in NPC Patients
NCT02301208CI-TRIAL-00016276NPC-RCT-WCRTunknownPhase 3ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a randomized Phase III study to evaluate efficancy of weekly cisplatin or nedaplatin concurrent with Intensity-modulated radiation therapy in Nasopharyngeal Carcinoma (NPC).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Nasopharyngeal Carcinoma | Nasopharyngeal Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Cisplatin | Drug | Cisplatin | ALIAS |
| Nedaplatin | Drug | Nedaplatin | ALIAS |
Design
Arms and outcomes
Arms (4)
- type
- ACTIVE_COMPARATOR
- label
- Low dose cisplatin arm
- description
- concurrent chemotherapy: cisplatin 20mg/m2,weekly,for 6 cycles during radiotherapy
- interventionNames
- Drug: Cisplatin
- type
- ACTIVE_COMPARATOR
- label
- High dose cisplatin arm
- description
- concurrent chemotherapy: cisplatin 30mg/m2,weekly,for 6 cycles during radiotherapy
- interventionNames
- Drug: Cisplatin
- type
- EXPERIMENTAL
- label
- Low dose nedaplatin arm
- description
- concurrent chemotherapy: nedaplatin 20mg/m2,weekly,for 6 cycles during radiotherapy
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * Pathologically confirmed untreated NPC patients * T1-2N1-3M0 or T3-4NxM0 * 18-70 years old * with MRI examinations * ECOG ≤ 2 * With written consent Exclusion Criteria: * With a second cancer * Pregnancy * With other severe diseases (blood,liver ,kidney or heart diseases) * Could not be staged properly * Without written consent
References
Publications (0)
Data not yet available
No reference posted for this study.